<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03639922</url>
  </required_header>
  <id_info>
    <org_study_id>I-StrokeII2016</org_study_id>
    <secondary_id>2017-000075-85</secondary_id>
    <nct_id>NCT03639922</nct_id>
  </id_info>
  <brief_title>Imatinib in Acute Ischaemic Stroke</brief_title>
  <official_title>Imatinib in Acute Ischaemic Stroke: A Phase 3, Randomized, Double-blind, Placebo Controlled, Parallel-arm Efficacy Trial of Imatinib in Acute Ischaemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Niaz Ahmed</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical trial comparing treatment with Imatinib to placebo when administered within 8
      hours of stroke onset for 6 days, in addition to conventional stroke treatment after acute
      ischaemic stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study aims to investigate if Imatinib reduces intracerebral haemorrhage and oedema in
      stroke patients after IV thrombolysis and/or trombectomy. Two important complications of
      ischaemic stroke and its acute treatment are haemorrhage into the infarcted tissue and
      cerebral oedema. Leading to worsening functional outcome in survivors. Both are caused by a
      disruption of the blood brain barrier (BBB) by ischemia of the brain vascular endothelium and
      associated cells involved in maintaining the BBB. Imatinib can reduce the damage to the BBB
      and hence reduce the formation of oedema and haemorrhage.

      The study is a phase III randomised, double-blind placebo-controlled parallel-arm trilal of
      patents with acute ischaemic stroke. Assessing the Clinical variables at baseline and after 3
      months.

      Primary objective:

      To investigate if Imatinib (800 mg / day) treatment initiated within 8 hours of symptom onset
      and given for 6 days improves functional outcome at three months after acute ischaemic stroke

      Secondary objective:

        1. Investigate if Imatinib treatment improves functional outcome at three months in acute
           ischaemic stroke patients treated with iv thrombolysis

        2. Investigate if Imatinib treatment improves neurological outcome at three months after
           acute ischaemic stroke

        3. Investigate if Imatinib treatment improves neurological outcome at three months in acute
           ischaemic stroke patients treated with iv thrombolysis

        4. Investigate if Imatinib reduces the frequency and grade of ICH in patients with acute
           ischaemic stroke treated with iv thrombolysis

        5. Investigate if Imatinib reduces the frequency and grade of cerebral oedema in patients
           with acute ischaemic stroke treated with iv thrombolysis

        6. Examine serious and non-serious adverse events in patients treated with Imatinib

        7. Investigate if Imatinib reduces mortality at 3 months after acute ischaemic stroke

        8. Investigate if Imatinib reduces mortality at 3 months in acute ischaemic stroke patients
           treated with iv thrombolysis
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, double-blind, placebo-controlled, parallel-arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The study is double-blind, only after the study is completed or terminated the treatments will be made available, or if requested by the data safety board, or if requested by treating clinician in association with possible SAE/SUSAR</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Functional independency at 3 months as measured by modified Rankin Scale (mRS) Score 0-2.</measure>
    <time_frame>3 months post treatment</time_frame>
    <description>For a positive outcome, patients in the active group treated with Imatinib 800 mg per day will have statistically significant higher functional independency compared to the control group treated with placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mRS score at 3 months compared to baseline</measure>
    <time_frame>At baseline and 3 months post treatment</time_frame>
    <description>For a positive outcome, patients treated with Imatinib will have a favorable shift of the scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency (%) of ICH on post-treatment imaging scan in patients undergoing IV thrombolysis and or endovascular thrombectomy.</measure>
    <time_frame>1 day post treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade of ICH (COED 1-3) on post-treatment imaging scan in patients undergoing IV thrombolysis and or endovascular thrombectomy.</measure>
    <time_frame>1 day post treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency (%) of cerebral oedema on post-treatment imaging scan in patients undergoing IV thrombolysis and or endovascular thrombectomy.</measure>
    <time_frame>1 day post treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade (COED 1-3) of cerebral oedema on post-treatment imaging scan in patients undergoing IV thrombolysis and or endovascular thrombectomy.</measure>
    <time_frame>1 day post treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious and non-serious adverse events</measure>
    <time_frame>3 months post teatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality at 3 months.</measure>
    <time_frame>3 months post treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1260</enrollment>
  <condition>Acute Ischaemic Stroke</condition>
  <arm_group>
    <arm_group_label>Imatinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Imatinib 400mg (2 tablets of 400mg) per day for 6 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 placebo tablets per day for 6 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib 400mg</intervention_name>
    <description>2 tablets of Imatinib 400mg per day for 6 days</description>
    <arm_group_label>Imatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>2 tablets of placebo per day for 6 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical diagnosis of acute ischaemic stroke with a neurological deficit corresponding
             to 6 points or higher on the NIHSS score

               1. at the time of randomization if no recanalisation therapy performed

               2. prior to iv thrombolysis therapy alone or prior to thrombectomy alone if
                  performed

               3. prior to iv thrombolysis if both iv thrombolysis and thrombectomy performed
                  Ischaemic stroke is defined as an event characterised by sudden onset of acute
                  focal neurological deficit, presumed to be caused by cerebral ischaemia and an
                  imaging scan excluding any intracranial haemorrhage.

          2. Age 18-85 years

          3. Patients should be randomized as soon as possible but not later than 8 hours of
             symptom onset.

               1. If the patient receives iv thrombolysis alone, patient should be randomized and
                  study drug should be given within one hour after completion of iv thrombolysis
                  infusion

               2. If the patient receives endovascular thrombectomy (with or without prior iv
                  thrombolysis), patient should be randomized within two hours after completion of
                  endovascular thrombectomy and study drug given as soon as possible after
                  randomization.

          4. iv thrombolysis, if performed, is done in agreement with European Stroke Organisation
             guidelines and has been initiated within 4.5 hours of stroke onset (see below separate
             criteria for indications / contraindications)

          5. Endovascular thrombectomy, if performed, is done in agreement with recently published
             American Stroke Association guidelines, and fulfilling the following criteria

               1. Confirmed diagnosis on Computed Tomography Angiography (CTA) or Magnetic
                  Resonance Angiography (MRA) of acute occlusion of either of the first two
                  segments of the Middle Cerebral Artery (M1 or M2), terminal Carotid Artery, first
                  segment of the Anterior Cerebral Artery (A1), or Basilar Artery, consistent with
                  the clinical symptoms.

               2. thrombectomy has been initiated within 8 hours of symptom onset (defined as start
                  with femoral artery (groin) puncture)

          6. Patient is competent to make a decision and has provided informed consent with regard
             to participation in the study, retrieval and storage of data and follow up procedures

        Exclusion Criteria:

        General

          1. Imaging scans show signs of large current infarction as defined by more than 1/3 of
             the Middle Cerebral Artery territory or ½ of other vascular territories

          2. ) Known significant pre-stroke disability (mRS ≥2)

          3. Severe comorbidities such as advanced dementia (estimate pre-stroke if otherwise
             healthy), terminal illness, and other severe medical conditions with anticipated life
             expectancy less than 6 months.

          4. Acute pancreatitis

          5. Severe hepatic dysfunction, including hepatic failure, cirrhosis, portal hypertension
             (oesophageal varices) and active hepatitis

          6. Ongoing treatment with chemotherapy

          7. Drugs which may increase the plasma concentration of Imatinib - ketokonazol,
             itrakonazol, erythromycin and claritomycin

          8. Drugs which may decrease the plasma concentration of Imatinib: Dexametason, phenytoin,
             karbamazepin, rifampizin, phenobarbital, fosphenytoin, primidon, Hypericum perforatum
             (Johannesört, St John's wort)

          9. Female patients with childbearing potential, if pregnancy cannot be excluded by
             pregnancy test (urine point-of-care pregnancy test).

         10. Patient is participating in other interventional study

        Additional Exclusion criteria for patients treated with intravenous thrombolysis (IVT)

          1. Severe stroke as assessed clinically by NIHSS&gt;25

          2. Administration of heparin within the previous 48 hours preceding the onset of stroke
             with an elevated activated thromboplastin time (aPTT) at presentation, or
             corresponding low-molecular heparin.

          3. Patients receiving oral anticoagulants, e.g. warfarin sodium (INR&gt;1.7) or direct oral
             anticoagulation: dabigatran ( aPTT&gt;40s), apixaban, rivaroxaban.

          4. Platelet count below 100,000/mm3. Significant bleeding disorder at present or within
             the past 6 months, known haemorrhagic diathesis.

          5. History or evidence or suspicion of intracranial haemorrhage including sub-arachnoid
             haemorrhage

          6. Systolic blood pressure &gt;185 mmHg or diastolic blood pressure &gt;110 mmHg, in spite of
             repeated doses of i.v. medication to reduce blood pressure below these limits.

          7. History of the following conditions: prior ischemic stroke within 3 months,
             intra-axial neoplasm, intracranial or spinal surgery within the prior 3 months, recent
             severe head trauma within 3 months or unruptured intracranial aneurysm&gt;5 mm.

          8. Major surgery or significant trauma in the past 10 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niaz Ahmed, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Niaz Ahmed, MD PhD</last_name>
    <phone>+ 46 8-517 72026</phone>
    <email>niaz.ahmed@ki.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie Westman, PhD</last_name>
    <phone>+ 46 8-517 75034</phone>
    <email>marie.westman@sll.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mälarsjukhuset Eskilstuna</name>
      <address>
        <city>Eskilstuna</city>
        <zip>633 49</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christina Widhe Qvist, MD</last_name>
      <email>christina.widhe.qvist@dll.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset</name>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan-Erik Karlsson, MD</last_name>
      <email>Jan-erik.karlsson@vgregion.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centralsjukhuset Kristianstad</name>
      <address>
        <city>Kristianstad</city>
        <zip>291 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axel Andersson, MD</last_name>
      <email>axel.p.andersson@skane.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skånes Universitetssjukhus Lund</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jesper Pettersson, MD</last_name>
      <email>jesper.pettersson@skane.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skånes Universitetssjukhus Malmö</name>
      <address>
        <city>Malmö</city>
        <zip>205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jesper Pettersson, MD</last_name>
      <email>jesper.pettersson@skane.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skaraborgs sjukhus Skövde</name>
      <address>
        <city>Skövde</city>
        <zip>541 42</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Björn Cederin, MD</last_name>
      <email>bjorn.cederin@vgregion.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Capio S:t Görans Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>112 81</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ulrika Löfmark Höjeberg</last_name>
      <email>ulrika.lofmark@capiostgoran.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Södersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <zip>118 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mihaela Romanitan</last_name>
      <email>mihaela.romanitan@sodersjukhuset.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantinos Kostulas, MD</last_name>
      <email>konstantinos.kostulas@sll.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset Solna</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Sjöstrand</last_name>
      <email>christina.sjostrand@ki.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Danderyds sjukhus</name>
      <address>
        <city>Stockholm</city>
        <zip>182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann-Charlotte Laska, MD</last_name>
      <email>ann-charlotte.laska@ds.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sundsvalls Sjukhus</name>
      <address>
        <city>Sundsvall</city>
        <zip>856 43</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fredrik Björk, MD</last_name>
      <email>fredrik.bjorck@rvn.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uppsala Akademiska Sjukhus</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Sjöblom</last_name>
      <email>Lars.sjoblom@akademiska.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Västmanlands sjukhus Västerås</name>
      <address>
        <city>Västerås</city>
        <zip>721 89</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Ranhem, MD</last_name>
      <email>andreas.ranhem@ltv.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 13, 2018</study_first_submitted>
  <study_first_submitted_qc>August 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2018</study_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Niaz Ahmed</investigator_full_name>
    <investigator_title>Sponsor, Coordinating investigator</investigator_title>
  </responsible_party>
  <keyword>acute ischaemic stroke</keyword>
  <keyword>Imatinib</keyword>
  <keyword>blood-brain-barrier</keyword>
  <keyword>trombectomy</keyword>
  <keyword>iv trombolysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

